Condition
Broader IBD news covering Crohn's disease, ulcerative colitis, research, treatments, monitoring, and patient care.
Page 5 of 87 · 4169 articles
Early Phase 2a data suggest a dual-target IBD therapy (ABBV-466) produced higher endoscopic remission than single-pathway agents, which could matter if later trials confirm better outcomes for people with...
Cure8 found this source from pluang.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab. Open the original article for the full details.
This mid-stage trial suggests a dual-targeting combo may improve endoscopic remission rates in Crohn’s disease compared with IL-23 inhibition alone, which could influence future treatment options and company strategies...
This preclinical study identifies a parasite-derived fluid that reduced inflammation, oxidative stress, and microbiome disruption in a mouse model of ulcerative colitis and in intestinal cells, pointing to possible new...
Perianal fistulas are a common, debilitating complication of Crohn’s disease; longer-term data on treatments that can produce durable fistula remission are directly relevant to patients and clinicians managing this...
Overlap of EoE and IBD appears uncommon but more frequent than in the general population and is linked to more allergic disease and higher steroid exposure without clearer increases in esophageal scarring. That may...
This study suggests coconut oil and its myristic acid component reduced Crohn’s-like inflammation in a mouse model via effects on the microbiome and regulatory T cells, which could point toward new dietary or adjunctive...
The study links lower vitamin D and higher TNF‑alpha with greater UC severity and with each other, suggesting these measurable biomarkers may reflect inflammation in ulcerative colitis.
Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Community and awareness. The original article is from msn.com.
Cure8 found this source from pluang.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Medications. Open the original article for the full details.
Patients with upper GI Crohn’s often have a more aggressive course; this registry analysis suggests they usually respond to biologic drugs similarly to other patients but still carry a higher long-term chance of needing...
If validated, antibody-based signals found years before symptoms could allow earlier risk identification and research into why immune responses precede IBD. That may matter for patients and clinicians interested in early...
Cure8 found this source from intellectia.ai, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for the...
A pediatric label for Omvoh could make an additional biologic option available for children with moderate-to-severe ulcerative colitis who respond to treatment. Trial results reported one-year remission among responders,...
Firsthand accounts show the real-life impact of ulcerative colitis on daily life, schooling, and mental health. Stories about surgery and ostomy reversal can help reduce stigma and highlight the importance of peer...
Cure8 could only read part of this source from endpoints.news, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical...
Cure8 found this source from fiercepharma.com, but the page could not be read reliably yet. It is tagged for Ulcerative colitis, Inflammatory bowel disease, and Mirikizumab. Open the original article for the full...
New Phase 2a data suggest a combination therapy (ABBV-466) produced higher endoscopic remission at Week 24 than either component alone — a potential sign that multi-target approaches might improve Crohn's outcomes.
Cure8 could only read part of this source from marketscreener.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab.
Knowing which kids need biologics after EEN could help families and clinicians plan follow-up and monitoring. Simple blood tests like complement C4 and RDW may have predictive value, if confirmed.
PRO2 and PRO3 were recorded far more often than CDAI or HBI in routine care and correlated strongly with those clinician-scored indices, so they may be a practical way to monitor Crohn’s activity and support real-world...
Multi-omics and AI approaches could improve biomarker discovery and predictive models that matter for earlier diagnosis and personalised treatment strategies in IBD, but practical use is limited today by data and...
The study suggests a colon-targeted herbal treatment altered metabolic and immune pathways and reduced inflammation in a rat model of ulcerative colitis, which could point to new therapeutic approaches to explore for UC...
People with Crohn's disease may be interested because the paper provides molecular hypotheses linking acupuncture to immune-related pathways (neutrophils, M2 macrophages) and nominates FER as a potential...
Perianal fistulas are a common, disabling complication of Crohn’s disease. A medication that provides durable fistula remission through 48 weeks could change treatment options for people with Crohn’s and perianal...
These Phase 3 results suggest guselkumab (TREMFYA) may provide durable clinical and endoscopic benefit through three years for adults with moderate to severe Crohn’s disease and may help with perianal fistula...
Cure8 could only read part of this source from marketscreener.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab.
This study uses transcriptomics, single‑cell data, and machine learning to nominate lactylation‑related genes as biomarkers and drug targets in ulcerative colitis, which could guide future biomarker or drug‑repurposing...
The study explores whether people with UC in deep histologic remission can reduce or stop maintenance medications without losing remission — a question many patients and clinicians face because of medication costs, side...
Cure8 could only read part of this source from marketscreener.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical...
Mid-stage data suggest a dual-targeting approach may improve endoscopic remission for people with moderate–severe Crohn's disease, including many who previously failed advanced therapies. If confirmed in larger trials,...
An experimental mouse study suggests gastrodin may reduce colitis severity and associated anxiety/depression-like behaviours while changing gut microbiota, metabolites, and intestinal inflammation — an early preclinical...
The report suggests a dual-targeting antibody combination (IL-23 p19 + α4β7) may achieve higher endoscopic remission than either mechanism alone in a treatment-experienced Crohn's population, which could matter for...
This review summarizes how ulcerative colitis trials have been designed recently and flags common weaknesses (small samples, short follow-up, overreliance on Mayo score). Better-designed trials could produce results that...
Personal stories can help people with IBD feel seen and show that fatigue and pain from Crohn’s disease don’t always prevent meaningful physical activity or community involvement. It also highlights fundraising and...
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Complications. The original article is from British journal of haematology.
If validated, antibody signatures could enable earlier identification of people at higher risk of developing IBD and help predict which patients may develop more severe disease, creating opportunities for earlier...
If validated, antibody-based signatures could enable much earlier detection of IBD and help identify people at risk of more severe Crohn’s disease years before symptoms—potentially opening opportunities for research on...
If validated, blood antibody patterns could allow earlier identification of people at risk for Crohn’s disease or ulcerative colitis — potentially before bowel damage occurs — opening opportunities for earlier monitoring...
Researchers are exploring targeted oral delivery and immune‑modulating strategies for colitis in older hosts; this study suggests a nanoparticle approach can alter T cell aging signs and the gut microbiome in mice, which...
The study identifies a molecular mechanism that links immune cell metabolism (Th17 glycolysis) with intestinal inflammation and colitis-associated cancer in experimental models. That pathway could eventually yield new...
Based on the title and source metadata, this appears to be a guideline related to Ulcerative colitis, Inflammatory bowel disease, and Colectomy. The original article is from Techniques in Coloproctology.
Researchers are exploring targeted oral delivery methods to improve treatment of colitis in older individuals. If translatable, a colon-targeted nanogel that boosts regulatory T cells and favorably shifts the microbiome...
Blood platelet indices (PLR, MPV) are simple blood-test measures that may help detect IBD activity and show changes with biologic treatment. If validated, they could offer an inexpensive, noninvasive way to supplement...
Crohn’s disease can rarely affect the nose and nasopharynx. Recognizing this can shorten diagnostic delay and lead to appropriate immunosuppressive or biologic treatment that may prevent complications.
A simple, low-cost fecal blood assay for mice can speed and lower the cost of preclinical studies of colorectal cancer and GI diseases. For IBD/Crohn’s research, it offers a way to monitor intestinal bleeding and link it...
The study suggests people with IBD consumed more dietary emulsifiers than healthy controls and found initial links between higher UPF/emulsifier intake and worse IBD-related events, which could be important if diet...
Nutritional disorders in IBD (underweight/malnutrition, overweight/obesity, and muscle loss/sarcopenia) are common and affect treatment tolerance, recovery, and quality of life. Knowing how frequent these problems are...
